Contrast-Enhanced Imaging for Liver Cancer
(ACRIN6690 Trial)

Recruiting in Palo Alto (17 mi)

+8 other locations

Overseen byChristoph Wald, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: American College of Radiology Imaging Network

No Placebo Group

Trial Summary

What is the purpose of this trial?RATIONALE: Diagnostic procedures, such as contrast-enhanced CT scan and contrast-enhanced MRI, may help find liver cancer and find out how far the disease has spread. PURPOSE: This clinical trial is studying contrast-enhanced CT scan and contrast-enhanced MRI in diagnosing and staging liver cancer in patients with chronic liver disease.

Eligibility Criteria

Inclusion Criteria

Listed on the regional OPTN/United Network for Organ Sharing (UNOS) liver transplant wait list with HCC-exception MELD points

Presence of ≥ 1 focal liver lesion(s) compatible with imaging diagnosis of stage II hepatocellular carcinoma (HCC) (Organ Procurement and Transplantation Network [OPTN] Class 5B liver lesion) on contrast-enhanced CT scan and/or contrast-enhanced MRI OR 2 or 3 focal liver lesions, each between > 1 and < 3 cm diameter, if each is compatible with imaging diagnosis of HCC on contrast-enhanced CT imaging and/or contrast-enhanced MRI

Imaging findings must be within the Milan criteria

+2 more

Exclusion Criteria

Negative pregnancy test

No renal insufficiency, as determined by eGFR 30-60 mL/min

No renal failure, as determined by estimated GFR (eGFR) < 30 mL/min

+4 more

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Waitlisted with HCC-Exception PointsExperimental Treatment3 Interventions

Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation